The group is persevering with Granite, but funds might be hard to come by.

It’s back to school for biotech, with a packed conference schedule.

The group will need to wait for more data with its neoantigen immunotherapy Granite, but cash is running short.

Projects from the likes of BioNTech, Transgene and Scancell will feature, but still have much to prove.

As a key mid-stage readout approaches for the group’s neoantigen immunotherapy, Gritstone still has much to prove.

The dust has settled on a momentous ESMO conference, which saw biotech activity amid big pharma’s practice-changing data.

Lung cancer will soon join melanoma as a phase 3 indication for mRNA-4157, an asset Merck & Co last year endorsed to the tune of $250m.